Aclarion Reports 30.5% Revenue Growth in Q2 2026 Despite Increased Net Loss

Aclarion, Inc. reported its financial results for the second quarter of 2026, revealing a revenue increase of 30.5% to $25,208 compared to $19,319 in the same period last year. For the first half of 2026, total revenue reached $46,348, up 21% from $38,309 in the first half of 2025. The growth in revenue is attributed to an increase in the volume of Nociscan reports sold, particularly in the UK market, following favorable local coverage decisions. Despite the revenue growth, the company reported a net loss of $2,747,551 for the second quarter, compared to a loss of $1,600,757 in the prior year, reflecting increased operating expenses.

Total operating expenses for the second quarter rose significantly to $2,908,019, up from $1,741,648 in the same quarter of 2025. This increase was driven primarily by a 155.2% rise in sales and marketing expenses, which totaled $877,160, largely due to the hiring of new sales personnel and increased clinical service costs associated with the ongoing CLARITY Trial. General and administrative expenses also increased by 53.8% to $1,733,789, influenced by higher legal fees and investor relations costs.

In terms of operational metrics, Aclarion's cash and cash equivalents stood at $16,310,462 as of June 30, 2026, an increase from $12,040,789 at the end of 2025. The company completed a registered direct offering during the first half of 2026, generating approximately $10.4 million in gross proceeds. The total number of shares outstanding increased to 2,462,250 as of June 30, 2026, reflecting the issuance of new shares in connection with the offering.

Looking ahead, Aclarion anticipates continued revenue growth as it expands its customer base and increases scan volumes. However, the company also acknowledges the need for additional capital to support its operations and strategic initiatives. Management believes that existing cash resources will be sufficient to fund operations into the second half of 2027, but recognizes the potential need for further financing to achieve long-term business objectives. The company remains focused on enhancing its market presence and developing its product offerings while managing operational costs effectively.